Niagen Bioscience is expected to report Q3 2026 revenue of $33.71 million and EPS of $0.01, with its current $2.33 stock price trading significantly below the average analyst target of $10.00.
The primary focus for investors is the commercial expansion of the Niagen Plus telehealth platform and the market reception of its high-margin at-home injection kits.
This report follows a steady second quarter where the company maintained profitability but slightly missed revenue targets amid intensifying competition in the NAD+ supplement market.
Investors are also seeking updates on the pharmaceutical pipeline, specifically the clinical progress of the NB4168 candidate and the newly launched skincare collaboration aimed at capturing the aging-science market.